These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1225 related items for PubMed ID: 17468062

  • 1. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 2. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
    Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W.
    Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS.
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
    Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur A, Thompson DE, Yates J, Orloff JJ.
    Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
    [Abstract] [Full Text] [Related]

  • 5. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB.
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [Abstract] [Full Text] [Related]

  • 6. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
    Choi HJ, Im JA, Kim SH.
    Maturitas; 2008 Jun 20; 60(2):170-6. PubMed ID: 18572334
    [Abstract] [Full Text] [Related]

  • 7. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.
    Bone; 2006 Dec 20; 39(6):1268-75. PubMed ID: 16884968
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.
    Clin Ther; 2009 Apr 20; 31(4):751-61. PubMed ID: 19446148
    [Abstract] [Full Text] [Related]

  • 9. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
    Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ.
    N Engl J Med; 2002 Feb 28; 346(9):653-61. PubMed ID: 11870242
    [Abstract] [Full Text] [Related]

  • 10. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
    Rizzoli R, Greenspan SL, Bone G, Schnitzer TJ, Watts NB, Adami S, Foldes AJ, Roux C, Levine MA, Uebelhart B, Santora AC, Kaur A, Peverly CA, Orloff JJ, Alendronate Once-Weekly Study Group.
    J Bone Miner Res; 2002 Nov 28; 17(11):1988-96. PubMed ID: 12412806
    [Abstract] [Full Text] [Related]

  • 11. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
    Hagino H, Nishizawa Y, Sone T, Morii H, Taketani Y, Nakamura T, Itabashi A, Mizunuma H, Ohashi Y, Shiraki M, Minamide T, Matsumoto T.
    Bone; 2009 Jun 28; 44(6):1078-84. PubMed ID: 19264155
    [Abstract] [Full Text] [Related]

  • 12. Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass.
    Hadji P, Gamerdinger D, Spieler W, Kann PH, Loeffler H, Articus K, Möricke R, Ziller V.
    Osteoporos Int; 2012 Feb 28; 23(2):625-33. PubMed ID: 21442459
    [Abstract] [Full Text] [Related]

  • 13. Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density.
    Bachmann G, Kriegman A, Gonçalves J, Kianifard F, Warren M, Simon JA.
    Menopause; 2011 Aug 28; 18(8):851-6. PubMed ID: 21796066
    [Abstract] [Full Text] [Related]

  • 14. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G.
    Nephrol Dial Transplant; 2009 May 28; 24(5):1472-7. PubMed ID: 19075192
    [Abstract] [Full Text] [Related]

  • 15. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May 28; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

  • 16. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan 28; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 17. Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis.
    Sanad Z, Ellakwa H, Desouky B.
    Climacteric; 2011 Jun 28; 14(3):369-77. PubMed ID: 21254911
    [Abstract] [Full Text] [Related]

  • 18. Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.
    Craig SJ, Youssef PP, Vaile JH, Sullivan L, Bleasel JF.
    Intern Med J; 2011 Feb 28; 41(2):186-90. PubMed ID: 20214696
    [Abstract] [Full Text] [Related]

  • 19. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
    Adachi JD, Faraawi RY, O'Mahony MF, Nayar A, Massaad R, Evans JK, Yacik C.
    Clin Ther; 2009 Aug 28; 31(8):1747-53. PubMed ID: 19808133
    [Abstract] [Full Text] [Related]

  • 20. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar 28; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.